daiichi sankyo co ltd
(4568:Tokyo Stock Exchange)
Mary Jane Helenek
Chief Executive Officer of Luitpold Pharmaceuticals Inc and President of Luitpold Pharmaceuticals Inc,Daiichi Sankyo Company, Limited
|Age||Total Calculated Compensation||This person is connected to 0 board members in 0 different organizations across 4 different industries.|
Ms. Mary Jane Helenek serves as the Chief Executive Officer and President at Luitpold Pharmaceuticals Inc., a subsidiary of Daiichi Sankyo Company Limited and PharmaForce, Inc.
3-5-1, Nihonbashi-honchoPhone: --
Tokyo, -- 103-8426
Board Members Memberships*There is no Board Members Memberships data available.
Education*There is no Education data available.
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Jon P. Stonehouse||Chief Executive Officer, President and Executive Director|
BioCryst Pharmaceuticals, Inc.
|Michael M. Morrissey Ph.D.||Chief Executive Officer, President and Director|
|Marc M.P. de Garidel||Chairman, Chief Executive Officer and Chairman of Strategic Committee|
|Alexandre Merieux||Chief Executive Officer, Director and Member of Strategy Committee|
|Adelene Q. Perkins||Chairman of The Board, Chief Executive Officer and President|
Infinity Pharmaceuticals, Inc.
|$568.5K||Compensation as of Fiscal Year 2014.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.